NewswireToday - /newswire/ -
Hackensack, NJ, United States, 2017/08/29 - Real-time Video Consultations Integrated with Allscripts Products, Available to Over 550,000 Physicians [NASDAQ: MDRX] - Allscripts.com / Vidyo.com.
Vidyo, the integrated video collaboration technology leader announced today that Allscripts (allscripts.com), an agnostic provider of electronic healthcare record technology has chosen the Vidyo.io™ platform to power virtual consultations directly embedded into the FollowMyHealth® patient portal. The on demand video visits can be launched directly from the patient portal workflow, simplifying remote consultations between physicians and patients.
“Allscripts strives to continually provide a fully engaged patient platform, giving patients and their families the ability to stay connected to their physicians, allowing them to be active contributors to their care,” said Kim South, General Manager, Allscripts. “Vidyo’s integrated video collaboration platform embedded into the Allscripts FollowMyHealth workflow is the ideal solution for patients and physicians to conveniently connect face-to-face over the web or our mobile app.”
According to IDC,“patient convenience is becoming more critical as they take on more financial accountability and are demanding levels of service they experience in other industries.”* Vidyo’s ability to tightly integrate into EHR workflows to provide high-quality remote consultations creates greater accessibility and increased communication for physicians and patients. The Vidyo integration with FollowMyHealth streamlines collaboration, improves patient care and satisfaction, and provides better health outcomes.
“We are thrilled to announce our integration with Allscripts’ FollowMyHealth patient engagement platform,” said Vidyo CEO Eran Westman. “Vidyo helps create a system of connected care that is more accessible to more people, and is highly interoperable with any EHR system and patient portal. Vidyo’s technology is easily embedded into any application in order to make engagement continuous and simplify the widespread clinical adoption of telehealth.”
Vidyo continues to see significant adoption and growth within the global healthcare industry. Vidyo is used by 40 out of the top 100 healthcare systems in the United States. In its last fiscal year, Vidyo added more than 50 care providers to its rapidly-growing customer base of more than 295 U.S healthcare systems. The Vidyo platform powers solutions delivered by five out of mHealthIntelligence’s Top 10 Telemedicine Solutions, such as Iron Bow Technologies, American Well, Philips, Care Innovations and Avizia. More than 50 million patients per year receive healthcare from a Vidyo-enabled telehealth provider.
*IDC, Market Note: Allscripts Addressing Value-Based Health, Cynthia Burghard, 2017
About Vidyo, Inc.
Vidyo (vidyo.com) is the leader in integrated video collaboration for businesses that require the highest quality, real-time video communications available to directly embed into their business processes. Millions of users around the world visually connect every day with Vidyo’s secure, scalable technology and cloud-based services. Vidyo has been awarded over 170 patents worldwide and is recognized by industry analysts for its cloud platform and APIs. Thousands of enterprises, service providers, and technology partners leverage Vidyo’s technology to create innovative HD quality video-enabled applications.
The VIDYO logo is a registered trademark of Vidyo, Inc., VIDYO and the trademarks of the VIDYO family of products are trademarks of Vidyo, Inc. and the other trademarks referenced herein are the property of their respective owners.
Many of the products and features described herein remain in varying stages of development and will be offered on a when-and-if available basis. The product plans, specifications, and descriptions are provided for information only and are subject to change without notice, and are provided without warranty of any kind, express or implied. Vidyo reserves the right to modify future product plans at any time.